Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades4
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron appoints new CFO after some internal shuffling
24 May 2019 - Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)
14 May 2019 - Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs
7 May 2019 - Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump
2 May 2019 - UK Earnings, Trading Statements Calendar - Next 7 Days
30 Apr 2019 - Faron Gets Results Of Traumakine Study From Japanese Licensing Partner
29 Apr 2019 - Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial
11 Apr 2019 - Faron Pharmaceuticals upbeat on latest info from MATINS trial
11 Apr 2019
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron appoints new CFO after some internal shuffling
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, annou...
Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)
LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The...
Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development ...
Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursda...
UK Earnings, Trading Statements Calendar - Next 7 Days
Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock
Faron Gets Results Of Traumakine Study From Japanese Licensing Partner
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical t...
Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial
LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The tes...
Faron Pharmaceuticals upbeat on latest info from MATINS trial
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 ...
Follow the stocks
